View All News
June 26, 2023

Invetx Appoints Dr. Marcus Remmers, Novo Holdings Partner and Animal Health Industry Leader, to Board of Directors

Invetx Appoints Dr. Marcus Remmers, Novo Holdings Partner and Animal Health Industry Leader, to Board of Directors

Boston, MA – June 26, 2023– Invetx, a pioneer in protein-based therapeutics for animal health, today announced the appointment of Dr. Marcus Remmers to its board of directors.

“We are pleased to welcome Dr. Remmers, an accomplished life sciences executive with significant veterinary biologics and animal health expertise, to our board of directors,” said Juergen Horn, PhD, chief executive officer, Invetx. “He will be a valuable addition as we advance our pipeline of novel antibody therapeutics targeting chronic and serious diseases in dogs and cats.”

Dr. Remmers is currently a partner at Novo Holdings, a member of the World Economic Forum’s Expert Network, and most recently served as chief technology officer at DSM, a global health, nutrition and bioscience company. He was previously vice president, global head of biologics R&D and vice president, global head of pharma R&D at Merial, a leading veterinary medicine company acquired by Boehringer Ingelheim Animal Health in 2017. Earlier in his career, he served as country president for Intervet (later Schering-Plough Animal Health). He received degrees in chemistry from the University of Munster and University of Freiburg, and a doctorate in chemistry from the Max Planck Institute for Polymer Research.

“I am excited to join the board of directors of Invetx and be part of the company’s remarkable journey,” said Dr. Remmers. “I believe that Invetx’s powerful platform and impressive product pipeline will unlock great opportunities and deliver innovative solutions that will make a difference in the Animal Health market.”

About Invetx
Invetx is a pioneer in creating novel, protein-based animal health therapeutics to transform standards of care in veterinary medicine. The company leverages a best-in-class, fully integrated biotechnology platform for the discovery, development, and manufacturing of veterinary monoclonal antibodies, and is developing a diverse product pipeline addressing chronic and severe diseases in the veterinary species.

Invetx has raised $86 million since 2018, including investors F-Prime Capital, Novo Holdings, GV, Eight Roads, Anterra Capital, Casdin Capital and funds managed by Tekla Capital Management, LLC. Strategic investment partners include AbCellera, a global technology company specializing in antibody discovery located in Vancouver, BC, and WuXi Biologics, a global company with leading biologics technology platforms. Invetx is a private company headquartered in Boston, Massachusetts. For more information, see

Invetx Partners and Investors:
Juergen Horn, PhD
Chief Executive Officer

Invetx Media:
Susan Kinkead

Invetx Completes Development of Canine and Feline Half-Life Extension Technology Platform that Significantly Extends Duration of Monoclonal Antibody Treatment Effect

Boston, MA- July 25, 2023 – Invetx, a pioneer in protein-based therapeutics for animal health, announced that it has recently completed development of its species-specific, half-life extension technology for dogs and cats which leads to superior extended duration of activity for the company’s veterinary monoclonal antibodies.

Invetx Announces Oversubscribed Series B Financing of $60.5 Million to Advance Portfolio of Best-in-Class Veterinary Biotherapeutics

Company positioned to bring portfolio of novel antibody product candidates through development to market approval Round includes new investors F-Prime Capital, Novo Holdings, GV and

Twist Bioscience Expands Partnership with Invetx to Include Discovery of Best-in-Class Antibodies to Treat Multiple Diseases in Cats and Dogs

SOUTH SAN FRANCISCO and BOSTON, Mass. – November 18, 2021 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering